Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
28. Mai 2020 08:30 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming oral presentation at this year’s Pediatric Endocrine...
Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
14. Mai 2020 16:15 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an update on the potential impact of the global COVID-19 pandemic on...
Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
10. Februar 2020 08:30 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical...
Rezolute to Present at BIO CEO & Investor Conference 2020
27. Januar 2020 08:30 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical...
Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
18. Dezember 2019 15:00 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT) today announced top-line results from its Phase 1 trial of AB101, an ultra-long...
Rezolute Management to Present at 2020 Biotech Showcase Conference
02. Dezember 2019 09:25 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2020 Biotech Showcase...
Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors
25. November 2019 09:25 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a biopharmaceutical company specializing in the development of innovative drug...
Rezolute Management to Present at 2019 BIO Investor Forum Conference
11. Oktober 2019 16:24 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 BIO Investor Forum...
Rezolute Management to Present at 2019 Canaccord Genuity Growth Conference
05. August 2019 09:25 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 Canaccord Genuity...
Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
24. Juli 2019 09:25 ET
|
Rezolute, Inc.
REDWOOD CITY, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative...